Interview with Chris Chapple Overactive Bladder: Tackling the Problem

European Urology

Volumn 49, Issue 5, 2006, Pages 921-923

  McKillop, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; CAPSAICIN; DARIFENACIN; DESMOPRESSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; RESINIFERATOXIN; SEROTONIN RECEPTOR; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; VANILLOID RECEPTOR;

ARTICLE; CLINICAL TRIAL; EUROPE; EVALUATION; HUMAN; NEUROTOXICITY; NOCTURIA; OVERACTIVE BLADDER; POPULATION RESEARCH; PRIORITY JOURNAL; RECEPTOR BINDING; STANDARDIZATION; URGE INCONTINENCE; URINARY FREQUENCY;

EID: 33645783025     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.02.049     Document Type: Note

References (12)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: Report for the Standardisation Sub-committee of the International Continence Society. Neurourol Urodynam 21 (2002) 167-178
2. Chapple C.R., Artibani W., Cardozo L.D., et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 95 (2005) 335-340
3. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
4. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
5. Hu T.W., Wagner T.H., Bentkover J.D., Leblanc K., Zhou S.Z., and Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63 (2004) 461-465
6. Wein A.J., and Rovner E.S. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 44 (1999) 56-66
7. U.S. Census Bureau, Projections of the total resident population by 5-year age groups, and sex with special age categories. 2000. Population Projections Program, Population Division, U.S. Census Bureau.
8. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5-26 Epub 2005 Mar 22. Review. Erratum in: Eur Urol 2005;48(5):875
9. Kobelt G., Kirchberger I., and Malone-Lee J. Quality-of life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 83 (1998) 583-590
10. O'Conor R., Johannesson M., Hass S., and Kobelt-Nguyen G. Urge incontinence: quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 14 (1998) 531-539
11. Liberman J.N., Hunt T.L., Stewart W.F., et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 57 (2001) 1044-1050
12. Coyne K.S., Payne C., Bhattacharyya S.K., et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7 (2004) 455-463